A recent prospective, multicenter phase II clinical study, registered as NCT05536154, evaluated an advanced EAP treatment protocol for stimulating stem cell production in individuals suffering from multiple myeloma and lymphoma. The research encompassed 68 patients initially, with 65 completing the investigation. This cohort included 34 patients with multiple myeloma and 31 with lymphoma, all of whom had not undergone previous stem cell mobilization and were deemed suitable candidates for autologous hematopoietic stem cell transplantation.
Improved EAP Therapy: A Breakthrough in Stem Cell Mobilization
The research team implemented a refined EAP regimen, which combines etoposide, cytarabine, and pegfilgrastim, as the primary method for stem cell mobilization. This protocol included dosage adjustments for elderly patients and those with compromised kidney function. Medical professionals closely monitored peripheral blood CD34+ cell counts on a daily basis, initiating leukapheresis based on standardized criteria. Notably, only a small fraction (3.1%) of patients required supplemental plerixafor during the entire procedure. The enhanced EAP regimen showed exceptional mobilization capabilities, with all 65 participants achieving the required threshold for sufficient stem cell retrieval, and 90.8% demonstrating optimal mobilization. The majority of patients completed cell collection in a single apheresis session, with an average total CD34+ cell yield of 14.7 ×10⁶ cells/kg. No significant disparities in mobilization effectiveness were noted between the multiple myeloma and lymphoma patient cohorts. This groundbreaking study, spearheaded by Chief Physician Dr. Ying Lu, was published online in the Chinese Medical Journal on July 9, 2026.
Regarding patient safety, the most frequently observed adverse events were hematological toxicities. While Grade 4 neutropenia and thrombocytopenia were common, these conditions were effectively managed through supportive care, such as blood transfusions and thrombopoietin administration. Only mild to moderate infections were reported, and no severe or life-threatening complications occurred, indicating that the regimen is generally well-tolerated by patients. Fifty-two patients ultimately underwent autologous hematopoietic stem cell transplantation. Engraftment of neutrophils and platelets proceeded smoothly, with lymphoma patients exhibiting slightly quicker hematopoietic recovery. The study's limitations, including a relatively small sample size and varied baseline characteristics of participants, were acknowledged. Two extensive phase III randomized trials are currently in progress to further validate these findings. In summary, the refined EAP regimen represents a robust and tolerable first-line mobilization option for patients with multiple myeloma and lymphoma, offering a viable alternative to existing mobilization strategies.
Clinical Outcomes and Future Directions for EAP Regimen
Fifty-two participants ultimately received autologous hematopoietic stem cell transplantation following the successful stem cell mobilization. Both neutrophil and platelet engraftment progressed without major complications, with lymphoma patients showing a slightly accelerated recovery of hematopoietic function. This demonstrates the regimen's effectiveness in preparing patients for subsequent transplantation procedures and supporting their post-transplant recovery. The favorable engraftment rates observed in this study are crucial for the long-term success of autologous hematopoietic stem cell transplantation, underscoring the potential of the optimized EAP regimen to improve patient outcomes.
Despite the promising results, the study's authors highlighted certain limitations, such as the relatively modest sample size and the heterogeneity of baseline conditions among the participants. These factors suggest a need for broader investigations to confirm the generalizability of the findings. Consequently, two large-scale phase III randomized trials are currently underway. These trials aim to provide more definitive evidence regarding the efficacy and safety of the optimized EAP regimen across a larger and more diverse patient population. The ongoing research will be instrumental in further validating this protocol as a standard first-line mobilization strategy, potentially transforming the landscape of stem cell transplantation for multiple myeloma and lymphoma patients by offering a highly effective and well-tolerated treatment option.